Skip to main content
Premium Trial:

Request an Annual Quote

Tara Biosystems Formed to Develop Organ-on-a-Chip Technology

NEW YORK (GenomeWeb) – VC firm Harris & Harris Group today announced the formation of Tara Biosystems, which is developing organ-on-a-chip technology for evaluating new therapies and drug compounds.

Harris & Harris has invested an undisclosed amount into Tara Bio. The company will initially use its organ-on-a-chip platform to provide physiologically relevant heart-on-a-chip human tissue models for toxicology and new drug discovery applications.

Its technology comes from research done at Columbia University, the laboratory of Milica Radisic at the University of Toronto, and the Massachusetts Institute of Technology. Tara Bio has developed a stem cell-derived system based on its proprietary "biowire" technology that enables testing on 3D heart tissue for evaluating the safety and efficacy of investigational therapies. The technology reduces risks, uncertainty, and costs and potentially could accelerate the process to bring therapies with value to market, Harris & Harris said.

Filed under

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more